PURPOSE: The acquisition of ever increasing volumes of high resolution magnetic resonance imaging (MRI) data has created an urgent need to develop automated and objective image analysis algorithms that can assist in determining tumor margins, diagnosing tumor stage, and detecting treatment response. METHODS: We have shown previously that Minkowski functionals, which are precise morphological and structural descriptors of image heterogeneity, can be used to enhance the detection, in T1 -weighted images, of a targeted Gd(3+) -chelate-based contrast agent for detecting tumor cell death. We have used Minkowski functionals here to characterize heterogeneity in T2 -weighted images acquired before and after drug treatment, and obtained without contrast agent administration. RESULTS: We show that Minkowski functionals can be used to characterize the changes in image heterogeneity that accompany treatment of tumors with a vascular disrupting agent, combretastatin A4-phosphate, and with a cytotoxic drug, etoposide. CONCLUSIONS: Parameterizing changes in the heterogeneity of T2 -weighted images can be used to detect early responses of tumors to drug treatment, even when there is no change in tumor size. The approach provides a quantitative and therefore objective assessment of treatment response that could be used with other types of MR image and also with other imaging modalities.
PURPOSE: The acquisition of ever increasing volumes of high resolution magnetic resonance imaging (MRI) data has created an urgent need to develop automated and objective image analysis algorithms that can assist in determining tumor margins, diagnosing tumor stage, and detecting treatment response. METHODS: We have shown previously that Minkowski functionals, which are precise morphological and structural descriptors of image heterogeneity, can be used to enhance the detection, in T1 -weighted images, of a targeted Gd(3+) -chelate-based contrast agent for detecting tumor cell death. We have used Minkowski functionals here to characterize heterogeneity in T2 -weighted images acquired before and after drug treatment, and obtained without contrast agent administration. RESULTS: We show that Minkowski functionals can be used to characterize the changes in image heterogeneity that accompany treatment of tumors with a vascular disrupting agent, combretastatin A4-phosphate, and with a cytotoxic drug, etoposide. CONCLUSIONS: Parameterizing changes in the heterogeneity of T2 -weighted images can be used to detect early responses of tumors to drug treatment, even when there is no change in tumor size. The approach provides a quantitative and therefore objective assessment of treatment response that could be used with other types of MR image and also with other imaging modalities.
Authors: Bradley Spieler; Carl Sabottke; Ahmed W Moawad; Ahmed M Gabr; Mustafa R Bashir; Richard Kinh Gian Do; Vahid Yaghmai; Radu Rozenberg; Marielia Gerena; Joseph Yacoub; Khaled M Elsayes Journal: Abdom Radiol (NY) Date: 2021-03-31
Authors: Timothy H Witney; Aileen Hoehne; Robert E Reeves; Ohad Ilovich; Mohammad Namavari; Bin Shen; Frederick T Chin; Jianghong Rao; Sanjiv S Gambhir Journal: Clin Cancer Res Date: 2015-05-13 Impact factor: 12.531
Authors: Emily Harding-Theobald; Jeremy Louissaint; Bharat Maraj; Edward Cuaresma; Whitney Townsend; Mishal Mendiratta-Lala; Amit G Singal; Grace L Su; Anna S Lok; Neehar D Parikh Journal: Aliment Pharmacol Ther Date: 2021-08-12 Impact factor: 9.524
Authors: Thomas C Booth; Timothy J Larkin; Yinyin Yuan; Mikko I Kettunen; Sarah N Dawson; Daniel Scoffings; Holly C Canuto; Sarah L Vowler; Heide Kirschenlohr; Michael P Hobson; Florian Markowetz; Sarah Jefferies; Kevin M Brindle Journal: PLoS One Date: 2017-05-17 Impact factor: 3.240
Authors: Benjamin A Hoff; Esther Pompe; Stefanie Galbán; Dirkje S Postma; Jan-Willem J Lammers; Nick H T Ten Hacken; Leo Koenderman; Timothy D Johnson; Stijn E Verleden; Pim A de Jong; Firdaus A A Mohamed Hoesein; Maarten van den Berge; Brian D Ross; Craig J Galbán Journal: Sci Rep Date: 2017-06-07 Impact factor: 4.379